NO920417L - Aminosyrederivater - Google Patents
AminosyrederivaterInfo
- Publication number
- NO920417L NO920417L NO92920417A NO920417A NO920417L NO 920417 L NO920417 L NO 920417L NO 92920417 A NO92920417 A NO 92920417A NO 920417 A NO920417 A NO 920417A NO 920417 L NO920417 L NO 920417L
- Authority
- NO
- Norway
- Prior art keywords
- amino
- lower alkyl
- protected
- carbamoyl
- hydroxyl
- Prior art date
Links
- 150000003862 amino acid derivatives Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- -1 amino, protected amino Chemical group 0.000 abstract 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/30—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups
- C07C279/32—N-nitroguanidines
- C07C279/36—Substituted N-nitroguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
- C07F9/4808—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
- C07F9/4816—Acyclic saturated acids or derivatices which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/5765—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Det er beskrevet forbindelser av formel i¿ NH¿R* hvor A representerer gruppen HO-HN (a) eller (b) hvor R1 representerer hydrogen, amino, beskyttet amino, acylamino eller lavere alkyl eventuelt substituert av aryl, hydroksyl-, beskyttet hydroksyl-, amino-, beskyttet amino-, acylamino-, maleimido-, suksinimido-, naftalimido-, 2,3-dihydro-l,3-diokso-lH-benz-[d,e]- isokinol-2-yl-, karboksyl-, beskyttet karboksyl-, kar- bamoyl-, mono-(lavere alkyl)-karbamoyl-, di-(lavere alkyl)-karbamoyl-, di-(lavere alkyl)-amino-, karboksy- lavere alkanoylamino-, pyrrolidino- eller morfolino- grupper; R2 representerer hydrogen eller lavere alkyl eventuelt substituert med aryl, amino-, beskyttet amino-, di-(lavere alkyl)-amino-, guanidino-, karboksyl-, beskyttet karboksyl-, karbamoyl-, mono- (lavere alkyl)-karbamoyl-, di-(lavere alkyl)-karbamoyl-, di-(lavere alkoksy)-fosfinyl-, dihydroksyfosfinyl-, pyrrolidino-, piperidino- eller morfolinogrupper, R3 representerer hydrogen eller lavere alkyl eventuelt sub- stituert med hydroksyl, beskyttet hydroksyl, amino eller beskyttet amino; R4 representerer hydrogen-, hydroksyl-, lavere alkoksy- eller benzyloksy-grupper; og R5 representerer hydrogen eller halogen; samt deres farmasøytisk akseptable salter. Disse forbindelser er anvendelige for forebygging eller bekjempelse av degene- rative leddlidelser eller for behandling av invasive svulster, aterosklerose eller multippel sklerose. De kan fremstilles ifølge kjente metoder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919102194A GB9102194D0 (en) | 1991-02-01 | 1991-02-01 | Amino acid derivatives |
GB919123162A GB9123162D0 (en) | 1991-02-01 | 1991-10-31 | Amino acid derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NO920417D0 NO920417D0 (no) | 1992-01-31 |
NO920417L true NO920417L (no) | 1992-08-03 |
Family
ID=26298370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO92920417A NO920417L (no) | 1991-02-01 | 1992-01-31 | Aminosyrederivater |
Country Status (16)
Country | Link |
---|---|
US (1) | US5304549A (no) |
EP (1) | EP0497192A3 (no) |
JP (1) | JPH04352757A (no) |
AU (1) | AU658387B2 (no) |
BG (1) | BG60794B2 (no) |
CA (1) | CA2058797A1 (no) |
CS (1) | CS20192A3 (no) |
FI (1) | FI920420A (no) |
HU (2) | HUT60466A (no) |
IE (1) | IE920339A1 (no) |
IL (1) | IL100770A0 (no) |
IS (1) | IS3805A (no) |
MY (1) | MY108260A (no) |
NO (1) | NO920417L (no) |
NZ (1) | NZ241409A (no) |
RO (1) | RO107934B1 (no) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
DE69108363T2 (de) * | 1990-12-03 | 1995-08-31 | Celltech Ltd | Peptidylderivate. |
AU3475393A (en) * | 1992-01-15 | 1993-08-03 | Merck & Co., Inc. | Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents |
WO1993020047A1 (en) * | 1992-04-07 | 1993-10-14 | British Bio-Technology Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
JPH09503492A (ja) * | 1993-08-02 | 1997-04-08 | セルテック・セラピューティクス・リミテッド | スクシンアミド誘導体、それらの調製法及びそれらのゼラチナーゼ及びコラゲナーゼ阻害剤としての使用 |
US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
US5455262A (en) * | 1993-10-06 | 1995-10-03 | Florida State University | Mercaptosulfide metalloproteinase inhibitors |
US5470834A (en) * | 1993-10-06 | 1995-11-28 | Florida State University | Sulfoximine and suldodiimine matrix metalloproteinase inhibitors |
US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
DK0822186T3 (da) * | 1994-01-20 | 2000-06-26 | British Biotech Pharm | L-tert-leucin-2-pyridylamid |
EP0664284A1 (en) * | 1994-01-21 | 1995-07-26 | F. Hoffmann-La Roche Ag | Process for preparing carboxamides |
GB9401129D0 (en) * | 1994-01-21 | 1994-03-16 | British Bio Technology | Hydroxamic acid derivatives as metalloproteinase inhibitors |
GB2300188B (en) * | 1994-01-22 | 1998-07-01 | British Biotech Pharm | Metalloproteinase inhibitors |
KR970700652A (ko) * | 1994-01-22 | 1997-02-12 | 포올 리틀우드 | 금속단백질 분해효소 억제제 |
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
GB9411088D0 (en) * | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
GB9423914D0 (en) * | 1994-11-26 | 1995-01-11 | British Biotech Pharm | Polyether derivatives as metalloproteinase inhibitors |
US5919940A (en) * | 1995-01-20 | 1999-07-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
GB9507799D0 (en) * | 1995-04-18 | 1995-05-31 | British Biotech Pharm | Metalloproteinase inhibitors |
GB9513331D0 (en) * | 1995-06-30 | 1995-09-06 | British Biotech Pharm | Matrix metalloproteinase inhibitors |
US5917090A (en) * | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
WO1997003966A1 (en) * | 1995-07-19 | 1997-02-06 | British Biotech Pharmaceuticals Limited | N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors |
JP2000500761A (ja) | 1995-11-23 | 2000-01-25 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
US5710322A (en) * | 1996-03-29 | 1998-01-20 | Hoffmann-La Roche Inc. | Optically active iminocarboxylic acid derivatives |
GB9613547D0 (en) * | 1996-06-27 | 1996-08-28 | Pharmacia Spa | Matrix metalloproteinase inhibitors |
ATE217315T1 (de) * | 1996-07-18 | 2002-05-15 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
US6462023B1 (en) | 1996-09-10 | 2002-10-08 | British Biotech Pharmaceuticals, Ltd. | Cytostatic agents |
BR9712019A (pt) | 1996-09-10 | 1999-08-24 | British Biotech Pharm | Derivados de cidos hirox-mico citoest ticos |
US6953788B1 (en) | 1996-09-19 | 2005-10-11 | Aventis Pharmaceuticals Inc. | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase |
US6500983B2 (en) | 1996-10-02 | 2002-12-31 | Novartis Ag | Hydroxamic acid derivatives |
EP0887077A1 (de) * | 1997-06-27 | 1998-12-30 | Roche Diagnostics GmbH | Verwendung von Azulenderivaten als Metalloproteaseinhibitoren |
US6235787B1 (en) * | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
GB9715030D0 (en) | 1997-07-18 | 1997-09-24 | British Biotech Pharm | Metalloproteinase inhibitors |
CA2313649A1 (en) * | 1997-12-12 | 1999-06-24 | Tadanori Morikawa | Novel metalloproteinase inhibitors |
EP0922702A1 (de) * | 1997-12-13 | 1999-06-16 | Roche Diagnostics GmbH | Neue Azulenderivate und diese enthaltende Arzneimittel |
US6239151B1 (en) | 1998-06-26 | 2001-05-29 | Hoffmann-La Roche Inc. | Compounds as inhibitor of tumor necrosis factor alpha release |
GB9826153D0 (en) | 1998-11-27 | 1999-01-20 | Hoffmann La Roche | Hydrazine derivatives |
EP1137640B1 (en) | 1998-12-11 | 2005-09-21 | F. Hoffmann-La Roche Ag | Cyclic hydrazine derivatives as tnf-alpha inhibitors |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
JP2001055327A (ja) * | 1999-06-11 | 2001-02-27 | Fuji Chemical Industries Ltd | 新規なヒドロキサム酸誘導体を含む医薬 |
PE20010659A1 (es) | 1999-10-01 | 2001-06-20 | Hoffmann La Roche | Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas |
US6797820B2 (en) | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
WO2002006214A1 (fr) | 2000-07-19 | 2002-01-24 | Mitsubishi Pharma Corporation | Derives a l'acide sulfonique d'acides hydroxamiques et leur utilisation comme produits medicaux |
US6716845B2 (en) | 2001-03-30 | 2004-04-06 | Hoffmann-La Roche Inc. | Barbituric acid derivatives |
AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
JP4314340B2 (ja) | 2001-06-15 | 2009-08-12 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | ピロリジン二環性化合物 |
AU2002359721A1 (en) | 2001-12-19 | 2003-07-09 | Bristol-Myers Squibb Company | Pichia pastoris formate dehydrogenase and uses therefor |
JP2009506098A (ja) * | 2005-08-31 | 2009-02-12 | セレンティス リミテッド | 黄色ブドウ球菌(Staphylococcusaureus)のコロニー形成を特徴とする炎症性皮膚症状を治療するためのオーレオリシン阻害剤の使用 |
ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
KR101442897B1 (ko) * | 2009-05-28 | 2014-09-23 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체 |
MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
KR101892500B1 (ko) | 2010-12-15 | 2018-08-28 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프릴리신 억제제 |
PE20151666A1 (es) | 2013-02-14 | 2015-11-19 | Novartis Ag | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep |
CA2900226A1 (en) | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
CN106831473B (zh) * | 2017-02-22 | 2019-07-16 | 江西瑞雅药业有限公司 | 3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
GB8629876D0 (en) * | 1986-12-15 | 1987-01-28 | Hoffmann La Roche | Phosphinic acid derivatives |
ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
-
1992
- 1992-01-06 CA CA002058797A patent/CA2058797A1/en not_active Abandoned
- 1992-01-15 AU AU10257/92A patent/AU658387B2/en not_active Ceased
- 1992-01-21 US US07/823,212 patent/US5304549A/en not_active Expired - Fee Related
- 1992-01-22 EP EP19920100953 patent/EP0497192A3/en not_active Withdrawn
- 1992-01-23 CS CS92201A patent/CS20192A3/cs unknown
- 1992-01-27 IL IL100770A patent/IL100770A0/xx unknown
- 1992-01-27 HU HU9200253A patent/HUT60466A/hu unknown
- 1992-01-27 NZ NZ241409A patent/NZ241409A/xx unknown
- 1992-01-30 RO RO92-200047A patent/RO107934B1/ro unknown
- 1992-01-30 MY MYPI92000150A patent/MY108260A/en unknown
- 1992-01-30 FI FI920420A patent/FI920420A/fi not_active Application Discontinuation
- 1992-01-30 JP JP4038346A patent/JPH04352757A/ja active Pending
- 1992-01-31 IS IS3805A patent/IS3805A/is unknown
- 1992-01-31 NO NO92920417A patent/NO920417L/no unknown
- 1992-01-31 IE IE033992A patent/IE920339A1/en unknown
-
1994
- 1994-03-01 BG BG98634A patent/BG60794B2/bg unknown
-
1995
- 1995-06-16 HU HU95P/P00229P patent/HU211308A9/hu unknown
Also Published As
Publication number | Publication date |
---|---|
RO107934B1 (ro) | 1994-01-31 |
CS20192A3 (en) | 1992-08-12 |
IE920339A1 (en) | 1992-08-12 |
EP0497192A2 (en) | 1992-08-05 |
IL100770A0 (en) | 1992-09-06 |
AU658387B2 (en) | 1995-04-13 |
FI920420A0 (fi) | 1992-01-30 |
MY108260A (en) | 1996-08-30 |
NZ241409A (en) | 1994-06-27 |
JPH04352757A (ja) | 1992-12-07 |
FI920420A (fi) | 1992-08-02 |
HUT60466A (en) | 1992-09-28 |
US5304549A (en) | 1994-04-19 |
AU1025792A (en) | 1992-08-06 |
NO920417D0 (no) | 1992-01-31 |
BG60794B2 (bg) | 1996-03-29 |
IS3805A (is) | 1992-08-02 |
HU211308A9 (en) | 1995-11-28 |
CA2058797A1 (en) | 1992-08-02 |
HU9200253D0 (en) | 1992-04-28 |
EP0497192A3 (en) | 1993-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO920417L (no) | Aminosyrederivater | |
BG103964A (en) | SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS | |
WO1993010091A3 (en) | Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | |
NO974220L (no) | 5-substituerte-3-(1,2,3,6-tetrahydropyridin-4-yl)- og 3-(piperidin-4-yl)-1H-indoler: nye 5-HT1Fagonister | |
NO922851L (no) | Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose | |
AU2178895A (en) | Heterocyclic-cyclic amine derivatives | |
MY104316A (en) | Deravatives substituted at methylamino nitrogen | |
NZ330216A (en) | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis | |
BG100154A (en) | Carbazole derivatibes having inhibiting effect to 17,20-lyase | |
IE811085L (en) | Pyridoxine derivatives | |
NO940135L (no) | Substituerte dialkyltioetere | |
AU6053394A (en) | New substituted phenoxyisobutyric acids and esters | |
CA2168193A1 (en) | Aryalkyl-thiadiazinones | |
ES8607953A1 (es) | Un procedimiento para la preparacion de nuevos derivados de triazina | |
CA2293711A1 (en) | Benzo(5,6)cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors | |
AU5980094A (en) | Morpholine derivative | |
TW325463B (en) | 4-Aminobenzoylguanidine-derivatives | |
DE59108921D1 (de) | Acyl-(2'-hydroxybiphenyl-2-yl)-phosphinsäuresalze, ihre herstellung und verwendung | |
EP1120418A4 (en) | Annealed pyridazine compounds, a method for their preparation and their use | |
WO2000008005A3 (de) | Piperazinonderivate | |
ZA957449B (en) | Bicyclic carboxamides | |
NO923331D0 (no) | N-substituerte aminometandifosfonsyrer | |
DK0912568T3 (da) | Imidazopyridiner | |
YU9092A (sh) | Derivati amino kiselina | |
TW282458B (no) |